These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Author: Callera F, Cavenaghi L, de Melo CM.
    Journal: Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728.
    Abstract:
    BACKGROUND: Daily monitoring of peripheral blood CD34+ cells may not be necessary for all patients with hematologic malignancies for adequate peripheral blood progenitor cells (PBPC) mobilization and harvesting. We therefore designed a regimen for PBPC mobilization in patients with multiple myeloma or pre-treated Non-Hodgkin's lymphoma based on a combination of low-dose cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) without daily monitoring of peripheral blood CD34+ cells. STUDY DESIGN AND METHODS: A prospective study was performed on patients with multiple myeloma (n = 22) or pre-treated Non-Hodgkin's lymphoma (n = 17) whose PBPC were harvested according to the following regimen: 1.5 g/m(2) Cy at day 1, 12 microg/kg/day G-CSF from day +7 to +11 avoiding daily monitoring of peripheral blood CD34+ cells and two consecutive leukapheresis at days +12 and +13. The optimum threshold of 2x10(6) CD34+ cells per kg was established. RESULTS: The proportion of patients with higher CD34+ cell yield after two leukapheresis was similar: multiple myeloma (16/22-72.7%) and Non-Hodgkin's lymphoma (12/17-70.6%). Exposure to radiotherapy and greater than two prior chemotherapy regimens were significantly associated with lower yield in multiple myeloma (p = 0.002) and Non-Hodgkin's lymphoma patients (p = 0.002), respectively. CONCLUSION: Our data suggested that adequate yields of CD34+ cells may be achieved in multiple myeloma or pre-treated Non-Hodgkin's lymphoma mobilized with low-dose Cy plus G-CSF regardless of the daily monitoring of peripheral blood CD34+ cells.
    [Abstract] [Full Text] [Related] [New Search]